abstract |
The present invention provides methods and systems for enhancing the safety of psychedelic drug therapies (eg, 5-HT2A agonists (eg, LSD and psilocybin), dissociatives and empathogens), for example, as part of a complex therapy. In particular, the invention relates to methods and systems for reducing the risk of developing psychosis, hypomania or mania associated with psychedelic therapy. |